Following the European Union’s (EU) General Affairs Council decision to select Amsterdam as the new location for the European Medicines Agency (EMA), Dr David Pye, Honorary Policy Officer of the Biochemical Society, said:

“The Society is concerned about the loss of the European Medicines Agency from the UK to Amsterdam. The short to medium term disruption to the 500 million people it currently serves will be significant during the transitional period. Patients and families will certainly suffer from the slowdown in processing approvals of new treatment but so will the UK’s wider economy. The UK needs a strong pharmaceutical industry, now more than ever, as the country leaves the EU. Losing the EMA from London represents a risk for future investment in this sector of the economy. The possible designation of the UK to third country status as a result of Brexit negotiations, would end access to the EMA’s services and the UK’s influence on future EU regulatory changes. This could have damaging consequences for the NHS, health of patients and the pharmaceutical sector.”